[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Arrae\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":48},"100620863","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-mb-1-on-metabolic-health-in-overweight-and-obese-adults-100620863",false,"NCT07363148","A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults","A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults","Inclusion Criteria:\n\n1. Males \\& females aged 18-50 years, inclusive\n2. BMI of 25.0 to ≤ 34.9 kg\u002Fm²\n3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically-approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n4. Stable body weight defined as a \\\u003C5% change in body weight in the three months prior to baseline as assessed by the QI\n5. Abdominal obesity: Waist circumference of \\> 94 cm (37 inches) in men and \\> 80 cm (31.5 inches) in women\n6. Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits\n7. Agrees to maintain current lifestyle habits (diet, medications, supplements, and sleep) as much as possible throughout the study\n8. Provided voluntary, written, informed consent to participate in the study\n9. Healthy as determined by medical history as assessed by Qualified Investigator (QI)\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance preventing consumption of the investigational product or placebo ingredients\n3. Gastric bypass surgery or other surgeries to induce weight loss\n4. Metal implants or other physical characteristics\u002Flimitations that may affect DEXA scan results as assessed by the QI\n5. Currently taking weight loss medications or participated in a weight loss program within the past three months as assessed by the QI\n6. Current or history of eating disorders as assessed by the QI\n7. Unstable metabolic disease or chronic diseases as assessed by the QI\n8. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n10. Participants residing in the same household as another study participant unless they are enrolled consecutively (e.g. not actively enrolled at the same time)\n11. Type I or Type II diabetes\n12. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n13. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n14. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n15. Self reported confirmation of glaucoma\n16. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n17. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n18. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n19. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n20. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n21. Chronic use of cannabinoid products (\\>2 times\u002Fweek) as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n22. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n23. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n24. Alcohol or drug abuse within the last 12 months\n25. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Section 7.3)\n26. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n27. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n28. Individuals who are unable to give informed consent\n29. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","ALL","18 Years","50 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults. The main question it aims to answer is:\n\nWhat is the difference in change in body weight from baseline at Day 84 between MB-1 and placebo?\n\nParticipants will be provided MB-1 or placebo and be assessed for anthropometric measurements, blood pressure, heart rate, and asked to complete appetite and satiety questionnaires and undergo a DEXA scan.",[27,28,29,30,31],"Obese","Overweight Adults","Obese Adults","Body Weight Control","BMI",[33,34,35,36],"Arrae","MB-1","Obesity","Overweight","NOT_YET_RECRUITING","2026-06-26",{"date":40,"type":41},"2026-06-30","ACTUAL",{"date":43,"type":21},"2026-08",{"date":45,"type":21},"2027-01",{"name":33,"class":47},"INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100632661","study-to-investigate-the-efficacy-of-a-digestive-health-dietary-supplement-on-post-meal-bloating-in-healthy-participants-100632661","NCT07516587","Study to Investigate the Efficacy of a Digestive Health Dietary Supplement on Post-meal Bloating in Healthy Participants","A Randomized, Double-blind, Placebo-controlled, Crossover Clinical Trial to Investigate the Safety and Efficacy of a Digestive Health Dietary Supplement on Post-meal Bloating in Healthy Participants","Inclusion Criteria:\n\n* Healthy male and female individuals aged 18-65 years at time of screening.\n* Body mass index (BMI) \\\u003C29.9 kg\u002Fm².\n* Self-reported recurrent postprandial abdominal bloating and\u002For distension occurring on average at least 2 days per week over the past 3 months, predominating over other gastrointestinal (GI) symptoms, and in the absence of a diagnosed gastrointestinal disease.\n* Females of child-bearing potential must have a negative baseline pregnancy test and agree to use a medically approved method of birth control for the duration of the study.\n* Willing to consume a standardized test meal consisting of 2 slices of large cheese pizza from Dominos on each test day.\n* Willing to complete online surveys and at-home measurements (waist circumference) at scheduled time points.\n* Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study.\n* Provides voluntary, written, informed consent to participate in the study prior to any study procedures.\n* Has reliable access to internet and a smartphone or computer capable of completing electronic surveys and attending virtual check-ins.\n\nExclusion Criteria:\n\n* Current or past diagnosis of any significant disease of the GI tract, including but not limited to: irritable bowel syndrome (IBS), celiac disease, inflammatory bowel disease (Crohn's disease or ulcerative colitis), functional constipation, gastroesophageal reflux disease (GERD), gastroparesis, or treatment for H. pylori infection or gastric ulcer within the past year.\n* Significant or untreated medical and\u002For psychiatric disorders, including but not limited to: severe unstable diabetes, recent myocardial ischemia or infarction, unstable angina, cancer (except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative or volunteers with cancer in full remission for more than five years after diagnosis are acceptable), uncontrolled hypertension, renal failure, chronic active hepatitis, acute hepatitis, cirrhosis, Acquired Immunodeficiency Syndrome (AIDS), malignancy, and neurological disorders including epilepsy, recent cerebrovascular disease, or recent traumatic brain injury.\n* Current use of digestive enzyme supplements, prebiotics\u002Ffibers, probiotics, postbiotics, bloating-targeted supplements, therapeutic iron supplementation (\\>65 mg elemental iron per dose), prokinetic agents, antacids, H2 blockers, proton pump inhibitors (PPIs), opioids, or loperamide within 14 days prior to the first test meal session; or use of any of the above during the study period.\n* Esophageal obstruction or difficulty swallowing.\n* Wear dentures.\n* Pregnant, breastfeeding, or planning to become pregnant during the study.\n* Known allergy, or sensitivity to any ingredient of the study supplement or placebo, including ginger, lemon balm, dandelion, or Bifidobacterium longum-derived products.\n* Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of standardized meal ingredients.\n* Alcohol use disorder or drug abuse\u002Fdependence within the past 6 months (\\>2 standard drinks\u002Fday on average).\n* Currently following an extremely restrictive diet or having done so within the past 3 months.\n* Participation in another clinical research trial within 30 days prior to randomization.\n* Cognitively impaired or unable to provide informed consent.\n* Any other condition that, in the Investigator's opinion, may adversely affect the participant's ability to complete the study or its measures, or that may pose significant risk to the participant.",true,"65 Years",{"count":59,"type":21},100,[24],"The goal of this crossover clinical trial is to evaluate the efficacy and safety of Bloat Gummies on postprandial bloating and related gastrointestinal discomfort in healthy adults with recurrent bloating. The main question it aims to answer is whether Bloat gummies reduce post-meal bloating, gas, or abdominal pain (stomach) discomfort. Participants will be asked to consume one dose of Bloat or Placebo after 2 test meals and answer questionnaires on gas, bloating and abdominal distension.",[63,64,65],"Digestive Health","Abdominal Discomfort","Gas and Bloating",[67,68,33,69],"bloating","abdominal distension","intestinal gas","2026-04-07",{"date":72,"type":41},"2026-04-13",{"date":74,"type":21},"2026-04",{"date":76,"type":21},"2026-10",{"name":33,"class":47},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":17,"maxAge":57,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100621447","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-bloat-on-gas-and-bloating-in-healthy-women-100621447","NCT07370740","A Clinical Trial to Investigate the Safety and Efficacy of Bloat on Gas and Bloating in Healthy Women","A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Bloat on Gas and Bloating in Healthy Women","Inclusion Criteria:\n\n1. Females aged 18-65 years, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least one year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n3. Recurrent bloating and\u002For distension occurring on average at least one day per week which predominates over other GI symptoms as assessed by the QI\n4. Experiences significant gas and bloating after consumption of the standardized meal provided at screening\u002Fbaseline, as assessed by a score of 0 (absent) or 1 (mild) pre-meal and a score of 2 (moderate) or 3 (severe) post-meal\n5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n6. Provided voluntary, written, informed consent to participate in the study\n7. Healthy as determined by medical history as assessed by Qualified Investigator\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Participants residing in the same household as another study participant unless they are enrolled consecutively (e.g. not actively enrolled at the same time)\n3. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of IP, placebo, or standardized meal ingredients\n4. Current or history of any significant diseases of the GI tract or digestive disorders (e.g., irritable bowel syndrome, celiac disease, inflammatory bowel disease, functional constipation, gastroesophageal reflux disease, being treated within the past year for H. pylori infection or gastric ulcer) as assessed by the QI\n5. Unstable metabolic disease or chronic diseases as assessed by the QI\n6. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n7. Type I or Type II diabetes\n8. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n9. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n10. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n11. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n12. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n13. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n14. Chronic use of cannabinoid products (\\>2 times\u002Fweek) as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n15. Regular use of tobacco or nicotine products in the past 6 months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n16. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n17. Alcohol or drug abuse within the last 12 months\n18. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the IP (Section 7.3)\n19. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n20. Individuals who are unable to give informed consent\n21. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","FEMALE",{"count":59,"type":21},[24],"The goal of this clinical trial is to investigate the safety and efficacy of Bloat on gas and bloating in healthy women. The main question it aims to answer is what is the change in postprandial gas and bloating from pre-dose at t = 60 mins post-dose between Bloat and placebo, as assessed by Gas and Bloating Likert scale at screening\u002Fbaseline.\n\nParticipants will be asked to consume one dose of Bloat or Placebo and answer questionnaires on gas and bloating.",[90,91,92],"Bloating","Gastrointestinal Symptoms","Intestinal Gas",[94,33,90,92,95],"Bloat","Gastrointestinal symptoms","2026-01-21",{"date":98,"type":41},"2026-01-27",{"date":100,"type":21},"2026-05",{"date":102,"type":21},"2026-07",{"name":33,"class":47},""]